Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HBeAg positive/negative CHB with blood HBVDNA≥10\^5 copies/mL and elevated ALT~* Nucleoside and nucleotide naïve CHB subjects. Previous lamivudine treatment is allowed in less than 10% of the total study population~Exclusion Criteria:~* subjects with hepatocellular carcinoma (HCC) potential or decompensated liver disease~* subjects with acute liver disease due to other causes~* subjects with medication history of immunosuppressive therapy, immunomodulatory therapy, systemic cytotoxic agents, chronic antiviral agents including Chinese herbal medicines known to have activity against HBV (e.g., lamivudine, hepatitis B immunoglobulin (HBIg)) within the previous 6 months prior to randomisation into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- A (TDF tablets) (Type: EXPERIMENTAL): Tenofovir disoproxil fumarate (TDF) tablets
- B (ADV tablets) (Type: ACTIVE_COMPARATOR): Adefovir dipivoxil (ADV) tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).